American Shared Hosp | 10-Q: FY2025 Q3 Revenue: USD 7.171 M

Revenue: As of FY2025 Q3, the actual value is USD 7.171 M.

EPS: As of FY2025 Q3, the actual value is USD 0.

EBIT: As of FY2025 Q3, the actual value is USD 406 K.

Segment Revenue

• Leasing Segment: Revenue decreased by $175,000 and $1,765,000 to $3,137,000 and $9,699,000 for the three and nine-month periods ended September 30, 2025, compared to $3,312,000 and $11,464,000 for the same periods in the prior year, respectively.
• Direct Patient Services Segment: Revenue increased by $347,000 and $2,848,000 to $4,034,000 and $10,655,000 for the three and nine-month periods ended September 30, 2025, compared to $3,687,000 and $7,807,000 for the same periods in the prior year, respectively.

Operational Metrics

• Net Loss: Net loss attributable to American Shared Hospital Services decreased by $190,000 and increased by $4,436,000 to a net loss of $17,000, or $0.00 per diluted share, and a net loss of $922,000 or $0.14 for the three and nine-month periods ended September 30, 2025, compared to a net loss of $207,000, or $0.03 per diluted share, and net income of $3,514,000, or $0.54 per diluted share for the same periods in the prior year, respectively.
• Gross Margin: Gross margin was $1,586,000 for the three months ended September 30, 2025, compared to $1,370,000 for the same period in the prior year.

Cash Flow

• Operating Cash Flow: Net cash provided by operating activities was $3,802,000 for the nine months ended September 30, 2025, compared to net cash used in operating activities of - $107,000 for the same period in the prior year.
• Free Cash Flow: Net change in cash, cash equivalents, and restricted cash was - $5,930,000 for the nine months ended September 30, 2025, compared to $269,000 for the same period in the prior year.

Unique Metrics

• PBRT System Revenue: Revenue generated from the Company’s PBRT system decreased by $189,000 and $1,695,000 to $2,127,000 and $5,691,000 for the three and nine-month periods ended September 30, 2025, compared to $2,316,000 and $7,386,000 for the same periods in the prior year, respectively.

Future Outlook and Strategy

• Core Business Focus: The Company plans to purchase and install two Leksell Gamma Knife Esprit Systems and two Linear Accelerator systems, with upgrades anticipated to occur in the first or second quarter of 2026 or later at existing customer sites.
• Non-Core Business: The Company is actively engaged with financing resources to fund these projects and has cash on hand of $5,345,000 and capacity under its Revolving Line of $7,000,000.